Zestagen’s mAbs and related intellectual property were discovered at the Hellenic Pasteur Institute, in Athens, Greece. Zestagen enjoys a strong intellectual property position, as it owns a PCT patent application covering the generation and usage of its monoclonal antibodies. The application will enter the national phases in 2013 and is projected to expire in Q4 2031. The company has been given a positive patent search and analysis by a well respected US law firm.
Zestagen will continue to seek the broadest possible protection for its therapeutic monoclonal antibodies. As the therapeutic field of use applies to all major markets, the Company will seek to protect its inventions in the key territories worldwide.